EuroBiotech: More Articles of Note


> Cassiopea posted more positive data on its pipeline. On Monday, the company reported interim data on clascoterone in androgenetic alopecia. Days later, Cassiopea added phase 2 genital wart data to its list of recent readouts. Release I More

> Takeda struck a deal to assess the feasibility of leon-nanodrugs’ MicroJet Reactor. Statement 

> Silence Therapeutics named David Horn Solomon as its CEO. Solomon ran Zealand Pharma from 2008 to 2015. Release


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

> Poxel posted data from a phase 1b NASH trial. The French biotech will now move the candidate into phase 2a. Statement

> Adaptimmune received clearance for dose escalation in its MAGE-A10 pilot studies. Release

Suggested Articles

What a difference a day makes in biotech.

A report out this week by PwC thinks that biotech could be in for a good year for deals as it sees the momentum from 2019 growing.

A drug developed at Temple restores a mechanism in brain cells that prevents the toxic buildup of the proteins amyloid beta and tau in Alzheimer's.